152 results about "Azacyclobutane" patented technology

Improved CO2 sorbents comprised of a mesoporous silica functionalized with a polyamine are obtained by the in-situ polymerization of azetidine. Also included herein are processes utilizing the improved CO2 sorbents wherein CO2 is chemisorbed onto the polyamine portion of the sorbent and the process is thermally reversible.

Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.

The invention relates to a fabric treatment composition which comprises a self-crosslinking polymer possessing pendant azetidinium groups. A first aspect of the invention comprises an azetidinium functionalized polymer containing primary or secondary amine groups. Cross-linking reactions between the azetidinium group and primary or secondary amine groups do not form quaternary groups and consequently do not result in a charged, cross-linked polymer. This lack of charge is believed to overcome the problems of stain fixing and dye adsorption. A second aspect of the present invention subsists in an azetidinium functionalized polymer of which the monomers comprise: an amino-acrylate and / or amino-alkacrylate monomer, and, optionally, further non-amino acrylate and / or alkacrylate monomer. A third aspect of the present invention provides a textile treatment composition which comprises an azetidinium functionalized polymer in accordance with the first or second aspect of the invention and a textile compatible carrier.

The present invention features a multi-layer ink-jet recording medium, suitable for recording images with dye and pigmented inks and thereby providing light-emitting, reflective, glossy, metallic-looking or holographic images, comprising a substrate coated with at least two layers comprising:(a) a first transparent ink-receptive layer comprising a polymeric binder and a cross-linker and optionally having a plasticizer and pigment particles such as alumina and silica coated over the substrate, wherein the cross-linker comprises and azetidinium polymer or a salt thereof, and / or a polyfunctinal aziridine or a salt thereof or a polyfunctional oxazoline or a salt thereof; and(b) a second ink-receptive layer comprising an opaque or semi-opaque coating composition, wherein the opaque or semi-opaque coating composition is capable of accepting a printed image and thereby becoming semi transparent or clearly transparent from application of ink-jet printing ink or similar inks, while presenting a light-emitting, reflective, glossy, metallic-looking or holographic image of high clarity and quality,wherein said first layer is located between said second layer and the substrate in said recording medium and the first and second layers are chemically coupled.

The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included.

The invention relates to compounds of Formula Iand their therapeutic uses, wherein substituent A is chosen from a substituted or unsubstituted aryl, heteroaryl, heterocyclic, or carboxylic group, B is chosen from a substituted or unsubstituted piperidine, homopiperidine, piperazine, pyrrolidine or azetidine group, R1 is chosen from hydro, alkyl, aryl, heteroaryl amino and halo, and L1 and L2 are as defined in the specification.

A Process for production of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salts thereof which comprises using as a starting compound as a (phenylthio)acetic acid derivative or salts thereof represented by the general formula:wherein X1 represents a halogen atom, is useful as a safe process for mass production of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salts thereof which is useful as a remedy for disease of central and peripheral nerve.

The invention relates to new azetidine derivatives of the formula Ito their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Topically-applied binder materials for imparting wet strength to soft, absorbent paper sheets, such as are useful as household paper towels and the like, include an azetidinium-reactive polymer, such as a carboxyl-functional polymer, an azetidinium-functional polymer and, optionally, a component useful for reducing sheet-to-sheet adhesion (blocking) in the product. These binder materials can be cured at ambient temperature over a period of days and do not impart objectionable odor to final product when wetted.

This invention relates to a hydrochloride, malate, oxalate and tartrate salt forms of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this salt, to processes for forming this salt and to its use in medical treatment. In addition, the present invention also relates to new polymorphic forms of each of these salts, as well as to pharmaceutical compositions comprising these polymorphic forms, to processes for obtaining them, and their use in medical treatment.

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows:wherein Q and Z are defined herein.

The present invention relates to new compounds of formula (I) wherein: Z is N and X is CH or N; Y is CONR5; P is phenyl or a 5 or 6 membered heteroaromatic ring containing one or more heteroatoms selected from N, O or S; Q is phenyl or a 5 or 6 membered aromatic heterocyclic ring containing one or more nitrogen atoms; R is C1-6alkylNR10R11 or C1-6alkylazetidine; R10 is hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C0-6alkylC3-6cycloalkyl, C0-6alkylaryl, C0-61alkylheteroaryl or C1-6alkylNR8R9; R11 is C1-6alkylNR8R9, C0-6alkylC3-6cycloalkyl or C0-6alkylheterocycloalkyl; as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

Disclosed are compounds, compositions and methods for treating diseases, syndromes, conditions and disorders that are affected by the inhibition of MGL, including pain. Such compounds are represented by Formula (I) as follows:wherein R1, W andare defined herein.